Psychopharmacology

, Volume 88, Issue 2, pp 153–157 | Cite as

Moclobemide, a new reversible MAO inhibitor — interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients

  • A. Korn
  • H. G. Eichler
  • R. Fischbach
  • S. Gasic
Original Investigations
Received:
Revised:

Abstract

Moclobemide is a new, short-acting, reversible MAOI, preferentially affecting type A MAO. We have studied the interaction of moclobemide with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.

Neither tyramine capsules (50 mg) nor cheese and wine meals (65 mg tyramine) produced a significant change in blood pressure and heart rate after single or repeated doses of moclobemide in volunteers. In contrast, after 1 weeks' treatment with tranylcypromine pressure response to cheese and wine meals was severe. Blood pressure sensitivity to IV tyramine was slightly increased (1.5–2 fold;P<0.05 versus predrug) during moclobemide treatment in patients and volunteers. This increase was neutralised by concomitant administration of desipramine in volunteers. Amitriptyline was well tolerated when given to patients after or together with moclobemide.

In conclusion, moclobemide appears relatively safe with respect to tyramine sensitivity and interaction with tricyclics.

Key words

Moclobemide MAO inhibition Thyramine sensitivity Cheese reaction Drug interaction Tricyclic antidepressants 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Blackwell B, Marley E, Price J, Tylor D (1967) Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 113:349–365Google Scholar
  2. Bobon DP, Rossignol P, Lepage-Goffioul G, Adens A, Gilot P, Breulet M (1979) L'effet antidepressif du Ro 11-1163 inhibiteur selectif de la MAO-A. Congres de Psychiatrie et de Neurology, Angers:1281–1286Google Scholar
  3. Casacchia M, Carolei A, Argenta G, Castellana F, Baldassare M, Fazio C (March 25–29, 1981) Antidepressant activity of Ro 11-1163, a new MAO-inhibitor. Abstract, International Symposium on typical and atypical antidepressants, TaorminaGoogle Scholar
  4. Da Prada M, Keller HH, Kettler R, Schaffner R, Pieri M, Burkhard WP, Korn A, Haefely WE (1982) Ro 11-1163, a specific and short-acting MAO-inhibitor with antidepressant properties. In: Kamijo K, Usdin E, Nagatsu T (ed) Monoamine oxidase, basic and clinical frontiers. Excerpta Medica, Amsterdam Oxford Princeton, pp 183–196Google Scholar
  5. Gasić S, Korn A, Eichler HG, Oberhummer I, Zapotoczky HG (1983) Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients. Eur J Clin Pharmacol 25:173–177Google Scholar
  6. Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A (1964) Monoamine oxidase inhibitors, tyramine and cheese. JAMA 188:1108–1110Google Scholar
  7. Lipman AG (Jan. 30, 1978) Potential interactions between monoamine oxidase inhibiting drugs and foods. Modern Medicine: 75–76Google Scholar
  8. Pare CMB, Hallstrom C, Kline N, Cooper TB (July 24, 1982) Will amitriptyline prevent the “cheese” reaction of monoamine-oxidase inhibitors? Lancet 183–186Google Scholar
  9. Pechamek U, Woidich H, Pfannhauser W, Blaicha G (1980) Untersuchung über das Vorkommen biogener Amine in Lebensmitteln. Ernährung/Nutrition 4 (2):58–61Google Scholar
  10. Pettinger WA, Soyangco FG, Oates JA (1968) Inhibition of monoamine oxidase in man by furazolidone. Clin Pharmacol Ther 9:442–447Google Scholar
  11. Ross RJ, Zavadill AP, Calil HM, Linnoila M, Kitanaka I, Blombery P, Kopin IJ, Potter WZ (1983) Effects of desmethylimipramine on plasma norepinephrine, pulse and blood pressure. Clin Pharmacol Ther 429:437Google Scholar
  12. Stefanis CN, Alveizos BH, Papadimitrion GN (1982) Antidepressant effect of Ro 11-1163, a new MAO-inhibitor. Pharmapsychiatry 17 (1):43–48Google Scholar
  13. Van de Merwe TJ, Pare CMB, Glover V, Sandler M (1983) Tranylcypromine isomers in depressed outpatients: effects on depression, monoamine oxidase inhibition and tyramine pressor response. Mod Probl Pharmacopsychiatry 19:189–202Google Scholar
  14. White K, Simpson G (1981) Combined MAOI-tricyclic antidepressant treatment: a reevaluation. J Clin Psychopharmacol 1:264–282Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • A. Korn
    • 1
  • H. G. Eichler
    • 1
  • R. Fischbach
    • 2
  • S. Gasic
    • 1
  1. 1.Department of Clinical PharmacologyI. Medizinische Univ.-KlinikVienna
  2. 2.Department of NeurologyLandesnervenklinik SalzburgAustria

Personalised recommendations